Yeah, I thought I already covered all that - I spoke to IR yesterday and she confirmed that FK Oncology is a subsidiary of FK Pharmaceuticals, but has nothing to do with APP Pharma (& the CVR's) beyond marketing and selling drugs inside the U.S. THROUGH APP Pharma.
That's why they bought APP Pharma in the 1st place. So they could market and sell their drugs inside the U.S. It's as simple as that.
So only U.S. sales of these two drugs will go towards their adjusted EBITDA.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.